The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

Figures & data

Table 1 Main clinical trials evaluating pertuzumab in the treatment of HER2-positive breast cancer

Trial^reference	Phase	Setting	Schema	Primary end point	Reported results
BO17929^Citation17 (N=66)	II	Metastatic	P+T	RR	RR: 24.2% Other: PFS: 5.5 months; safe
TOC3487^Citation19 (N=37)	II	Metastatic	P+T	RR and safety	RR: 18% in eleven patients evaluated; possible increase of cardiotoxicity
CLEOPATRA^Citation14 (N=808)	III	Metastatic	Placebo+T+Doc P+T+Doc	PFS	PFS improvement in the P+T+Doc group (HR: 0.62; P<0.001) Other: strong trend of OS in favor of the P+T+Doc group; similar safety profile
NeoSphere^Citation28 (N=417)	II	Neoadjuvant	T+Doc P+T+Doc P+T P+Doc	pCR	pCR improvement in the P+T+Doc group (45.8%) Other: similar safety profile
TRYPHAENA^Citation29 (N=225)	II	Neoadjuvant	P+T+FEC→P+T+Doc FEC→P+T+Doc P+T+Doc+Cp	Cardiac safety	Low incidence of symptomatic LVSD and significant declines in LVEF Other: similar pCR rates across groups (57.3%–66.2%)

Abbreviations: P, pertuzumab; T, trastuzumab; Doc, docetaxel; FEC, fluorouracil/epirubicin/cyclophosphamide; Cp, carboplatin; RR, response rate; PFS, progression-free survival; pCR, pathological complete response; HR, hazard ratio; OS, overall survival; LVSD, left ventricular systolic dysfunction; LVEF, left ventricular ejection fraction.

BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol20102871138114420124182

 PubMed Web of Science ®Google Scholar

PorteraCCWalsheJMRosingDRCardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerClin Cancer Res20081492710271618451236

 PubMed Web of Science ®Google Scholar

BaselgaJCortésJKimSBCLEOPATRA Study GroupPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875

 PubMed Web of Science ®Google Scholar

GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890

 PubMed Web of Science ®Google Scholar

SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196

 PubMed Web of Science ®Google Scholar